Mölnlycke Granulox® Haemoglobin Spray, 12 ml

Mölnlycke Granulox haemoglobin spray supports the treatment of chronic wounds by improving oxygen supply. Topical application promotes the healing process directly within the wound bed.

Topical haemoglobin spray for the treatment of chronic wounds

• Healing time for diabetic leg ulcers 50% shorter than with^{standard treatment1}
• Twice as many wounds healed after 8–16 weeks compared to^{the standard of care1,2,3}
• Average pain scores after four weeks more than 70 per cent lower than the standard of care for chronic^wounds3
• Fewer dressings required during wound management: 99 per cent fewer dressings for chronic wounds after four weeks, compared with 33 per cent with ^{the standard of care4}
• Treatment costs for diabetic leg ulcers at least 40% lower than with^{the standard of care5}

Granulox®:

• is an innovative medical device for the treatment of chronic wounds, e.g. venous leg ulcers, arterial leg ulcers, mixed venous-arterial leg ulcers, diabetic leg ulcers, secondary healing surgical wounds and pressure ulcers. Can also be applied to exuding and infected wounds.
• The active ingredient, haemoglobin, supplies the wound bed with oxygen from the ambient air through the process of facilitated diffusion. The improved oxygen supply to the wound bed promotes healing.

^Granulox® is a haemoglobin spray for the management/treatment of chronic wounds, including diabetic foot ulcers, venous ulcers, arterial ulcers and mixed ulcers, and for the secondary healing of surgical wounds and pressure sores ¹. It can also be used to treat exudative and infected wounds ².

Once Granulox has been sprayed onto the wound, the highly purified haemoglobin begins to bind oxygen from the surrounding environment and diffuses through the wound exudate to the wound bed. The supply of oxygen to the wound bed supports wound healing and improves patient outcomes ³.

A practical spray application makes Granulox a portable and easy-to-use addition to standard nursing wound care. For optimal results, Granulox can be applied at each dressing change, but at least every three days.

Studies show that the use of Granulox leads to a shorter duration of wound healing, a reduction in wound pain and savings in treatment costs ³.

1. Hunt, SD., Elg, F. Clinical effectiveness of haemoglobin spray (Granulox®) as adjunctive therapy in the treatment of chronic diabetic foot ulcers. November 2016. 2. Hunt, SD., Elg, F. Haemoglobin spray as adjunctive therapy in complex wounds: Meta-analysis versus standard care alone in pooled data by wound type across three retrospective cohort-controlled evaluations. SAGE Open Medicine, 2018; 6:1–9. 3. Hunt, SD., Elg, F. The clinical effectiveness of haemoglobin spray as an adjunctive therapy in the treatment of chronic wounds. Journal of Wound Care, 2017; 26(9):558–568. 4. Hunt, S., Elg, F., Percival, S. Assessment of the clinical effectiveness of haemoglobin spray as an adjunctive therapy in the treatment of sloughy wounds. Journal of Wound Care. April 2018; 27(4): 210–219. 5. Brüggenjürgen, B., Hunt, SD., Eberlein, T. Wound management in diabetic foot ulcers (DFU) – incremental cost analysis of treating diabetic neuropathic foot lesions with adjunct haemoglobin contact spray in Germany. Gesundh ökon Qual manag, 2017; 22:1-8. 

Dosage form

Spray

Usage

The application of Granulox® can be tailored to the frequency of dressing changes. Granulox® should be applied at every dressing change, at least every three days.

1. Carry out wound debridement and irrigation. HOCl/NaOCl products (e.g. Granudacyn®) are particularly recommended.
2. Apply Granulox® thinly and evenly from a distance of 5–10 cm. A one-second spray covers a wound measuring 2 x 3 cm.
3. Cover the wound with a breathable wound dressing.

Ingredients

Composition: 10 % carbonylated haemoglobin; 0.7 % phenoxyethanol; 0.9 % sodium chloride; 0.05 % N-acetylcysteine in 100 % water.